Publications by authors named "Scott Rollins"

Claim this Profile
P
Perceptions From Non-Magnet® Organizations: Nurse Leaders' Transformational Leadership Behaviors and Clinical Nurses' Structural Empowerment.
Scott M Rollins

J Nurs Adm· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creation and Expansion of a Mixed Patient Intermediate Care Unit to Improve ICU Capacity.
Emmett A Kistler, Elaine Klatt, Jesse D Raffa, Phyllis West, Jacqueline A Fitzgerald, Scott Rollins

Crit Care Explor· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Kenneth I Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Cancado, Scott A Rollins

N Engl J Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.
Barbara Muz, Feda Azab, Pilar de la Puente, Scott Rollins, Richard Alvarez

Biomed Res Int· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen, Petra Muus, Ulrich Dührsen, Antonio M Risitano, Jörg Schubert, Scott A Rollins

Blood· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Russell P Rother, Scott A Rollins, Christopher F Mojcik, Robert A Brodsky, Leonard Bell

Nat Biotechnol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen, Neal S Young, Jörg Schubert, Robert A Brodsky, Gerard Socié, Scott A Rollins

N Engl J Med· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation.
Christine S Rinder, Henry M Rinder, Michael J Smith, Jane C K Fitch, Jayne B Tracey, Scott A Rollins

Transfusion· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
Paul W Armstrong, Kenneth W Mahaffey, Wei-Ching Chang, W Douglas Weaver, Judith S Hochman, Scott Rollins

Am Heart J· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Pierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, Judith S Hochman, Kevin J Malloy, Scott Rollins

Eur Heart J· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery.
John C Chen, Scott A Rollins, Stanton K Shernan, Steven Boyce, Keith Allen

J Card Surg· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
Manesh R Patel, Kenneth W Mahaffey, Paul W Armstrong, W Douglas Weaver, Gudaye Tasissa, Scott Rollins

Am J Cardiol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Edward D Verrier, Stanton K Shernan, Kenneth M Taylor, Frans Van de Werf, Mark F Newman, Scott A Rollins

JAMA· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Stanton K Shernan, Jane C K Fitch, Nancy A Nussmeier, John C Chen, Scott A Rollins

Ann Thorac Surg· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen, Claire Hall, Judith C W Marsh, Modupe Elebute, Michael P Bombara, Scott A Rollins

N Engl J Med· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, Pierre Theroux, Judith S Hochman, Scott Rollins

Circulation· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis